Paul-Ehrlich-Institut

Information on the Use of Cookies

In order to operate and optimise our website, we would like to collect and analyse statistical information completely anonymously. Will you accept the temporary use of statistics cookies?

You can revoke your consent at any time in our privacy policy.

OK

Use of Mon­o­clon­al An­ti­bod­ies against COVID-19 – Xe­vudy (Sotro­vimab) Avail­able in Ger­many

Sotrovimab (trade name Xevudy), an additional COVID-19 treatment option, became available for use in Germany at the end of January 2022. It is a SARS-CoV-2 neutralising monoclonal antibody offered by the company GlaxoSmithKline (GSK) in Germany. Xevudy has been authorised in the EU since December 2021.

Xevudy (sotrovimab) monoclonal antibody is held in hand (Source: ice_blue/Shutterstock.com)

Xevudy is a human monoclonal antibody that binds to the receptor-binding domain of the SARS-CoV-2 spike protein. The European Commission approved Xevudy on 17 December 2021 for the treatment of COVID-19 in adults and adolescents aged 12 years and older who do not require supplemental oxygen and are at increased risk of severe disease progression.

Efficacy of Xevudy (sotrovimab) against viral variants

While Xevudy’s neutralising activity against the Delta variant is unrestricted, data currently indicates that neutralisation against the Omicron variant, although reduced by a factor of 3, is still retained. This is confirmed by the latest study results published by VIR Biotechnology/GSK and other independent research groups. Further information on the efficacy of Xevudy against currently circulating virus variants, including the Delta and Omicron variants, is available in the updated product information.

Updated: 01.02.2022